Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 2
1976 1
1977 1
1978 4
1979 2
1980 2
1981 5
1982 3
1983 4
1984 1
1985 2
1986 3
1987 4
1988 2
1989 1
1990 2
1992 3
1993 3
1994 3
1998 2
1999 1
2000 2
2001 2
2003 6
2004 10
2005 7
2006 6
2007 5
2008 6
2009 8
2010 4
2011 11
2012 14
2013 14
2014 17
2015 8
2016 1
2017 2
2018 5
2019 5
2020 2
2021 2
2022 4
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

181 results
Results by year
Filters applied: . Clear all
Page 1
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, Tahir H, Gooderham M, Krishnan E, Liu-Seifert H, Emery P, Pillai SG, Helliwell PS; SPIRIT H2H study group. Mease PJ, et al. Among authors: krishnan e. Ann Rheum Dis. 2020 Jan;79(1):123-131. doi: 10.1136/annrheumdis-2019-215386. Epub 2019 Sep 28. Ann Rheum Dis. 2020. PMID: 31563894 Free PMC article. Clinical Trial.
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H; COAST-V study group. van der Heijde D, et al. Among authors: krishnan e. Lancet. 2018 Dec 8;392(10163):2441-2451. doi: 10.1016/S0140-6736(18)31946-9. Epub 2018 Oct 22. Lancet. 2018. PMID: 30360964 Clinical Trial.
Gout and the heart.
Bhole V, Krishnan E. Bhole V, et al. Among authors: krishnan e. Rheum Dis Clin North Am. 2014 Feb;40(1):125-43. doi: 10.1016/j.rdc.2013.10.004. Rheum Dis Clin North Am. 2014. PMID: 24268013 Review.
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.
Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, Järvinen P, Sanchez-Burson J, Gaffney K, Lee EB, Krishnan E, Santisteban S, Li X, Zhao F, Carlier H, Reveille JD; COAST-W Study Group. Deodhar A, et al. Among authors: krishnan e. Arthritis Rheumatol. 2019 Apr;71(4):599-611. doi: 10.1002/art.40753. Epub 2019 Mar 8. Arthritis Rheumatol. 2019. PMID: 30343531 Free PMC article. Clinical Trial.
Filipino gout: a review.
Prasad P, Krishnan E. Prasad P, et al. Among authors: krishnan e. Arthritis Care Res (Hoboken). 2014 Mar;66(3):337-43. doi: 10.1002/acr.22118. Arthritis Care Res (Hoboken). 2014. PMID: 23983155 Free article. Review. No abstract available.
Hyperuricaemia--where nephrology meets rheumatology.
Avram Z, Krishnan E. Avram Z, et al. Among authors: krishnan e. Rheumatology (Oxford). 2008 Jul;47(7):960-4. doi: 10.1093/rheumatology/ken070. Epub 2008 Apr 27. Rheumatology (Oxford). 2008. PMID: 18443007 Review.
Items, Instruments, Crosswalks, and PROMIS.
Fries JF, Krishnan E, Bruce B. Fries JF, et al. Among authors: krishnan e. J Rheumatol. 2009 Jun;36(6):1093-5. doi: 10.3899/jrheum.090320. J Rheumatol. 2009. PMID: 19509084 No abstract available.
Cholesterol Granuloma of the Sphenoid Sinus: An Insidious Entity.
Lim RCA, Krishnan EK, Husain S. Lim RCA, et al. Among authors: krishnan ek. Indian J Otolaryngol Head Neck Surg. 2022 Oct;74(Suppl 2):1450-1452. doi: 10.1007/s12070-021-02597-7. Epub 2021 May 4. Indian J Otolaryngol Head Neck Surg. 2022. PMID: 36452606
Self-reported symptom study of COVID-19 chemosensory dysfunction in Malaysia.
Lee SH, Yeoh ZX, Sachlin IS, Gazali N, Soelar SA, Foo CY, Low LL, Syed Alwi SB, Tengku Kamalden TMI, Shanmuganathan J, Zaid M, Wong CY, Chua HH, Yusuf S, Muhamad D, Devesahayam PR, Ker HB, Salahuddin Z, Mustafa M, Sawali H, Lee HG, Din S, Misnan NA, Mohamad A, Ismail MN, Periasamy C, Chow TS, Krishnan EK, Leong CL, Lim LPF, Zaidan NZ, Ibrahim MZ, Abd Wahab S, Mohd Hashim SS; Malaysian COVID-19 Anosmia Research Group. Lee SH, et al. Among authors: krishnan ek. Sci Rep. 2022 Feb 8;12(1):2111. doi: 10.1038/s41598-022-06029-6. Sci Rep. 2022. PMID: 35136124 Free PMC article. Clinical Trial.
181 results